Myomo Stock News

Colliers Securities reissued their buy rating on shares of Myomo (NYSEAMERICAN:MYO) in a research report sent to investors on Thursday, TipRanks reports. They currently have a $17.00 price target on the stock. Other analysts have also issued reports about the company. Alliance Global Partners reiterated a buy rating and set a $34.00 price target (down []

Colliers Securities reaffirmed their buy rating on shares of Myomo (NYSEAMERICAN:MYO) in a research report report published on Thursday morning, TipRanks reports. Colliers Securities currently has a $17.00 price objective on the stock. Several other research firms also recently weighed in on MYO. Zacks Investment Research downgraded Myomo from a buy rating to a hold []

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 23.40% and 40.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) CEO Paul Gudonis on Q3 2021 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi

BOSTON, MA / ACCESSWIRE / September 28, 2021 / Myomo, Inc. (NYSE American:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering f

Myomo Inc.: Fundamentals And Technicals Are Aligned For This Unique Microcap

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologic

The stock price of Myomo Inc (NYSEAMERICAN: MYO) increased by over 32% during intraday trading. This is why it happened.

Myomo' (MYO) CEO Paul Gudonis on Q2 2021 Results - Earnings Call Transcript

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 25.81% and 51.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why I Didn't Buy Myomo: Dilution And Cash Burn

Myomo has a revolutionary product that allows people with paralyzed arms to use them once more.

Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2021 Results - Earnings Call Transcript